Promise Bio, a leader in precision medicine powered by epiproteomics and artificial intelligence, has unveiled the Frontier Epiproteomic Innovation Grant, a new R&D initiative designed to accelerate biotech companies developing next-generation therapeutics.

 

The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform, providing deeper biological insights from existing or newly-generated mass-spectrometry data. 

 

Participants will receive comprehensive profiling of up to 200 samples, including detection of up to 64 post-translational modifications (PTMs), proteoform-specific analysis, quality control, bioinformatics, and expert scientific interpretation—all without any additional wet-lab work.

 

“At Promise Bio, we believe developing breakthrough therapies shouldn't be limited by access to advanced technologies,” said Dr Ronel Veksler, Co-founder and CEO of Promise Bio. 

 

“The Epiproteomic Innovation Grant is our commitment to empowering innovators with deep PTM and proteoform insights that are typically out of reach, enabling data-driven R&D decisions to increase the probability of success and ultimately accelerating better outcomes for patients.”

 

PTMs and proteoforms are key drivers of disease biology, therapeutic response, and patient heterogeneity—yet they often remain invisible to standard proteomics. The grant is designed to help biotech companies uncover these critical signals, unlocking mechanistic insights with direct application to drug development.

 

The grant targets clinical-stage companies working in immunology, neurology, and cardio-renal-metabolic diseases. Priority will be given to projects that address clearly defined, decision-critical questions, such as elucidating mechanisms of action, biomarker discovery, patient stratification, and predicting drug responses.

 

Promise Bio’s computational platform enables large-scale profiling of up to 64 PTMs from standard mass-spectrometry data—without customized chemical enrichment or extra laboratory procedures. 

 

Based on foundational research from the Weizmann Institute of Science and highlighted in Nature Biotechnology in 2023, the platform empowers researchers to uncover disease mechanisms, identify new drug targets, and tailor therapies.